To include your compound in the COVID-19 Resource Center, submit it here.

VBI starts Phase III lot consistency trial of HBV vaccine

VBI Vaccines Inc. (NASDAQ:VBIV) began the double-blind, international Phase III CONSTANT trial to evaluate lot-to-lot

Read the full 159 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE